Get in Touch

With In Young Hwang

Name and email
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Associate Professor

In Young Hwang

Associate Professor
PhD (Molecular Medicine), University of Auckland, New Zealand
Cluster:
Food, Chemical and Biotechnology
Email
LinkedIn
Google Scholar

SIT Appointments

  • Associate Professor
    – Present

Education

  • PhD (Molecular Medicine)
    University of Auckland , New Zealand
  • Bachelor of Science (Biomedical Science) with First Class Honours
    University of Auckland , New Zealand

Research Interests

  • Metabolic engineering of microbes for biochemical production
  • Development of biosensors and genetic tool-box in microbial systems
  • Reprogramming probiotics and commensal microbes for therapy
  • Mammalian cell engineering for bioproduction

Current Projects

  • Fighting Amebiasis with bacteria: a combined approach with natural probiotics and engineered bacteria
    – Present

    NRF, PI

Past Projects

  • Development of microalgae for carbon capture-driven industrial applications
    –

    Sinergy Seed grant, Co-PI

  • Engineering commensal microbes to modulate neurohormonal balance
    –

    US Air Force (AOARD), Co-PI

  • Biosynthesis of commodity chemicals from oil palm empty fruit bunch lignin
    –
  • A Genetic Expression System that Enables Controllable Decoupling of Cell Growth and Cell Cycle for Improved Mammalian Protein Production
    –

    Thermo Fisher Scientific, Collaborator

Journal Papers

  • Koh E‡, Hwang IY‡, Lee J.W.J, Lee Y.S, March J.C, Chang MW. (2022) Engineering probiotics to inhibit Clostridioides difficile infection by dynamic modulation of intestinal metabolism. Nat Commun 13, 3834.   ‡authors contributed equally.

  • Wun KS, Hwang IY, Chang MW (2022) Biocomposite blocks as programmable building materials. Nat. Mater 21, 382-383.

  • Hwang IY, Kim HR, Chang MW. (2021) Engineered probiotics to alter endocannabinoid system. Biotechnol. Notes. 2, 33-38

  • Lo T-M‡, Hwang IY‡, Cho H-S‡, Fedora RE, Chng SH, Choi WJ, Chang MW. (2021) Biosynthesis of commodity chemicals from oil palm empty fruit bunch lignin. Front. Microbiol 12, 684.   ‡authors contributed equally

  • Sieow BF, Wun KS, Yong WP, Hwang IY*, Chang MW*. (2021) Tweak to treat: reprograming bacteria for cancer treatment. Trends Cancer 7 (5) 447-464. *Co-corresponding author

  • Tham E.H*, Koh E, Common J.E.A, Hwang IY. (2020) Biotherapeutic Approaches in Atopic Dermatitis. Biotechnol. J., 15(10), e1900322

  • Sun T, Kwok WC, Chua KJ, Lo T-M, Potter J, Yew WS, Chesnut JD, Hwang IY*, Chang MW*. (2020) Development of a proline-based selection system for reliable genetic engineering in Chinese hamster ovary cells. ACS Synth Biol, 9, 1864–1872. *Co-corresponding author

  • Aggarwal, N., Breedon, A.M.E., Davis, C.M., Hwang, I.Y., Chang, M.W. (2020) Engineering probiotics for therapeutic applications: recent examples and translational outlook. Curr Opin Biotechnol 65, 171-179.

  • Hwang I.Y., Chang M.W (2019) Engineering commensal bacteria to rewire host-microbiome interactions, Curr Opin Biotechnol. 62, 116-122.

  • Aggarwal N., Hwang I.Y., Chang M.W. (2019). Phage-boosted chemotherapy Nat Biomed Eng 3,680-681.

  • Lee, H. L., Shen, H., Hwang, I. Y., Ling, H., Yew, W. S., Lee, Y. S., & Chang, M. W. (2018). Targeted Approaches for In Situ Gut Microbiome Manipulation. Genes, 9(7), 351

  • Lubkowicz, D., Ho, C. L., Hwang, I. Y., Yew, W. S., Lee, Y. S., and Chang, M. W. (2018) Reprogramming Probiotic Lactobacillus reuteri as a Biosensor for Staphylococcus aureus Derived AIP-I Detection, ACS Synth Biol 7, 1229-1237.

  • Hwang, I. Y., Lee, H. L., Huang, J. G., Lim, Y. Y., Yew, W. S., Lee, Y. S., and Chang, M. W. (2018) Engineering microbes for targeted strikes against human pathogens, Cell. Mol. Life Sci, 1-15.

  • Hwang, I. Y., Koh, E., Wong, A., March, J. C., Bentley, W. E., Lee, Y. S., and Chang, M. W. (2017) Engineered probiotic Escherichia coli can eliminate and prevent Pseudomonas aeruginosa gut infection in animal models, Nat Commun 8, 15028.

  • Hwang, I. Y., Koh, E., Kim, H. R., Yew, W. S., and Chang, M. W. (2016) Reprogrammable microbial cell-based therapeutics against antibiotic-resistant bacteria, Drug Resist. Updat. 27, 59-71.

  • Ho, C. L., Hwang, I. Y., Loh, K., and Chang, M. W. (2015) Matrix-immobilized yeast for large-scale production of recombinant human lactoferrin, MedChemComm 6, 486-491.

  • Hwang, I. Y., Tan, M. H., Koh, E., Ho, C. L., Poh, C. L., and Chang, M. W. (2014) Reprogramming microbes to be pathogen-seeking killers, ACS Synth Biol 3, 228-237.

  • Lo, T.-M., Tan, M. H., Hwang, I. Y., and Chang, M. W. (2013) Designing a synthetic genetic circuit that enables cell density-dependent auto-regulatory lysis for macromolecule release, Chem. Eng. Sci. 103, 29-35.

  • Sutherland, H. S., Hwang, I. Y., Marshall, E. S., Lindsay, B. S., Denny, W. A., Gilchrist, C., Joseph, W. R., Greenhalgh, D., Richardson, E., Kestell, P., Ding, A., and Baguley, B. C. (2012) Therapeutic reactivation of mutant p53 protein by quinazoline derivatives, Invest New Drugs 30, 2035-2045.

  • Hwang, I. Y., Baguley, B. C., Ching, L. M., and Gilchrist, C. A. (2010) The ubiquitin-proteasome system is inhibited by p53 protein expression in human ovarian cancer cells, Cancer Lett 294, 82-900.

Books

  • Aggarwal N, Srivastava SK, Koh E, Sieow BF, Hwang IY* (2022) Microbiome engineering for metabolic disorders. Principles in Microbiome Engineering. Wiley

  • Wong, C. K., Tan, M. H., Rasouliha, B. H., Hwang, I. Y., Ling, H., Poh, C. L., and Chang, M. W. (2014) Therapeutic microbes for infectious disease, Methods in Molecular Biology. Springer.

  • Sieow B FL, De Sotto R, Seet ZR D, Hwang IY, Chang MW (Submitted) Synthetic Biology meets machine learning. Methods in Molecular Biology. Springer